CClinicalTrials.gg
Not yet recruitingNCT06613659Updated Sep 26, 2024

Cohort Study on the Treatment of Severe Pneumonia with Traditional Chinese Medicine

An observational study in Community-Acquired Infections, sponsored by Henan University of Traditional Chinese Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Henan University of Traditional Chinese Medicine · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,016
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, prospective cohort study, with syndrome differentiation and treatment of traditional Chinese medicine as the exposure factor. Patients using syndrome differentiation of traditional Chinese medicine combined with conventional treatment of Western medicine are classified as the treatment cohort of Integrated Chinese and Western medicine, and patients using conventional treatment of Western medicine only are classified as the treatment cohort of Western medicine

Read the detailed description

Severe pneumonia is a severe respiratory disease with high mortality, many complications and poor prognosis. Traditional Chinese medicine has certain curative effect in the adjuvant treatment of severe pneumonia, but there is a lack of systematic TCM syndrome differentiation scheme and its curative effect evaluation in the real medical environment. The cohort study on the efficacy of TCM syndrome differentiation scheme in the adjuvant treatment of severe pneumonia is conducive to providing new evidence for the optimization and evidence-based evaluation of TCM treatment scheme for severe pneumonia. Therefore, this study took severe pneumonia as the research object, standardized use of traditional Chinese medicine diagnosis and treatment scheme as the exposure factor, carried out a multi center prospective cohort study, used the 90 day mortality, 28 day mortality, treatment failure rate, etc., to evaluate the clinical efficacy and safety of integrated traditional Chinese and Western medicine in the treatment of severe pneumonia, and provided evidence for the application and promotion of traditional Chinese medicine in severe pneumonia.

02

Conditions studied

  • Community-Acquired Infections

Keywords

  • Community-Acquired Infections
  • Traditional Chinese Medicine
  • Cohort study
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Severe community-acquired pneumonia (CAP) is a severe respiratory disease with further development and deterioration of lung tissue inflammation, causing organ dysfunction and even life-threatening. Patients with SCAP are prone to hypoxemia, respiratory failure, septic shock, leading to multiple organ failure and poor prognosis. Western medicine treatment of SCAP mainly focuses on anti infection and mechanical ventilation. Although new intervention measures and management concepts are constantly optimized, the mortality rate of SCAP is still high. The treatment of SCAP is facing a severe situation, so it is necessary to seek new adjuvant therapy.

Inclusion criteria

  • It met the diagnostic criteria of severe pneumonia;
  • Age ≥ 18 years old, regardless of gender.
  • Voluntary treatment.
  • Sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women;
  • Patients with mental illness who are unable to cooperate or unwilling to cooperate with follow-up;
  • Those who are participating in clinical trials of other drugs;
  • Known allergic to therapeutic drugs.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,016 participants (estimated)
Patient registry
No

Groups and cohorts

  • Treatment cohort of integrated traditional Chinese and Western Medicine

    Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposure group was treated with syndrome differentiation of traditional Chinese medicine combined with conventional Western Medicine (treatment cohort of integrated traditional Chinese and Western Medicine).

    Drug: traditional Chinese medicine (TCM)

  • Western medicine treatment queue

    The non exposure group (Western medicine treatment cohort) used conventional western medicine treatment but not standardized TCM syndrome differentiation treatment.

    Drug: non traditional Chinese medicine (non-TCM)

Interventions

  • Drugtraditional Chinese medicine (TCM)

    Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.

  • Drugnon traditional Chinese medicine (non-TCM)

    Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.

05

What researchers measure

Primary outcomes

  1. 90-day mortality

    Calculate the proportion of patients who died of the disease on the 90th day of treatment

    Time frame: Mortality on the 90th day of treatment

Secondary outcomes

  1. 28-day mortality

    Time frame: Calculate the proportion of patients who died of the disease on the 28th day after discharge

  2. treatment failure rate

    The primary efficacy outcome was the rate of treatment failure, which includes treatment failure that occurred early,late, or at both times.

    Time frame: Early treatment failure was defined as clinical deterioration within 72 hours of treatment. Late treatment failure between 72 hours and to 28 days.

  3. time to clinical stability

    temperature of 37.2°C orlower, heart rate of 100 beats/min or lower, systolic blood pressure of 90 mm Hg or higher, and arterial oxygen tension of 60 mm Hg or higher when the patient was not receiving supplemental oxygen.

    Time frame: every day in the treatment.

  4. ICU stay time

    length of ICU and hospital stays will be recorded.

    Time frame: the 28 days of the treatment phase.

  5. hospitalization time

    length of hospital stays will be recorded.

    Time frame: the 28 days of the treatment phase

  6. Mechanical ventilation time

    Time of invasive mechanical ventilation

    Time frame: the 28 days of the treatment phase

  7. SOFA score

    Sequential Organ Failure Assessment.It is a scoring system for evaluating and monitoring the organ function of critically ill patients.The minimum score is 0 and the maximum is 24. The higher the score, the worse the result.

    Time frame: The sofa scores of the first, seventh, fourteenth, twenty-first and twenty-eight days of admission and the first, second and third months after discharge were counted.

  8. Quality of life

    Score according to the quality of life table,the minimum score is 12 points, and the maximum score is 60 points. The higher the score, the worse the result.

    Time frame: The scores of the first, seventh, fourteenth, twenty-first and twenty-eight days of admission and the first, second and third months after discharge were counted

  9. TCM syndrome score

    Traditional Chinese Medicine Syndrome Points.Including cough, expectoration, dyspnea, chest pain, anorexia and fatigue, each item is rated as 1-5 points from mild to severe.The minimum score is 6 points and the maximum score is 30 points. The higher the score, the worse the result.

    Time frame: The TCM syndrome scores of the first, seventh, fourteenth, twenty-first and twenty-eight days and the first, second and third months after discharge were counted

  10. 90 day readmission rate

    The proportion of rehospitalization due to exacerbation within 90 days after discharge was recorded

    Time frame: The proportion of rehospitalization due to exacerbation within 90 days after discharge was recorded

06

Study locations

1 site
  • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
    Zhengzhou, Henan 450000, China
07

Registry details

Key details

Study ID
NCT06613659
Lead sponsor
Henan University of Traditional Chinese Medicine
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Sep 20, 2024 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Sep 26, 2024

Study contacts

Haifeng Wang, doctor
Contact
wangh_f@126.com
86-371-66248624
jiangsheng Li, doctor
Contact
li_js8@163.com
86-371-66248624

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion